Genotype and plasma concentration of cystatin C in patients with late-onset Alzheimer disease

Dementia and Geriatric Cognitive Disorders

Volumn 23, Issue 4, 2007, Pages 251-257

  Chuo, Liang Jen ^a   Sheu, Wayne H H ^a   Pai, Ming Chyi ^b   Kuo, Yu Min ^b  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Alzheimer disease; Apolipoprotein E; Cystatin C 73 polymorphism; Cystatin C, plasma

Indexed keywords

APOLIPOPROTEIN E4; CYSTATIN C;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SIMILARITY; GENOTYPE; HOMOZYGOTE; HUMAN; MALE; ONSET AGE; PERIPHERAL CIRCULATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; CYSTATINS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; REFERENCE VALUES; STATISTICS, NONPARAMETRIC; TAIWAN;

EID: 33947683350     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100021     Document Type: Article

References (41)

1. Mount C, Downton C: Alzheimer disease: progress or profit? Nat Med 2006;12:780-784.
2. Bergem AL, Engedal K, Kringlen E: The role of heredity in late-onset Alzheimer disease and vascular dementia: a twin study. Arch Gen Psychiatry 1997;54:264-270.
3. Mortimer JA, Fortier I, Rajaram L, Gauvreau D: Higher education and socioeconomic status in childhood protect individuals at genetic risk of AD from expressing symptoms in late life: the Saguenay-Lac-Saint-Jean Health and Aging Study. Neurobiol Aging 1998;19:S215.
4. Mahley RW, Weisgraber KH, Huang Y: Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA 2006;103:5644-5651.
5. Goddard KA, Olson JM, Payami H, Van der Voet M, Kuivaniemi H, Tromp G: Evidence of linkage and association on chromosome 20 for late-onset Alzheimer disease. Neurogenetics 2004;5:121-128.
6. Finckh U, von der Kammer H, Velden J, et al: Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer disease. Arch Neurol 2000;57:1579-1583.
7. Crawford FC, Freeman MJ, Schinka JA, et al: A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease. Neurology 2000;55:763-768.
8. Cathcart HM, Huang R, Lanham IS, Corder EH, Poduslo SE: Cystatin C as a risk factor for Alzheimer disease. Neurology 2005;64:755-757.
9. Grubb A, Lofberg H: Human gamma-trace, a basic microprotein: amino acid sequence and presence in the adenohypophysis. Proc Natl Acad Sci USA 1982;79:3024-3027.
10. Bobek LA, Levine MJ: Cystatins - Inhibitors of cysteine proteinases. Crit Rev Oral Biol Med 1992;3:307-332.
11. Deng A, Irizarry MC, Nitsch RM, Growdon JH, Rebeck GW: Elevation of cystatin C in susceptible neurons in Alzheimer's disease. Am J Pathol 2001;159:1061-1068.
12. Ghiso J, Jensson O, Frangione B: Amyloid fibrils in hereditary cerebral hemorrhage with amyloidosis of Icelandic type is a variant of gamma-trace basic protein (cystatin C). Proc Natl Acad Sci USA 1986;83:2974-2978.
13. Frangione B, Revesz T, Vidal R, et al: Familial cerebral amyloid angiopathy related to stroke and dementia. Amyloid 2001;8(suppl 1):36-42.
14. Levy E, Sastre M, Kumar A, et al: Codeposition of cystatin C with amyloid β protein in the brain of Alzheimer disease patients. J Neuropathol Exp Neurol 2001;60:94-104.
15. Sastre M, Calero M, Pawlik M, et al: Binding of cystatin C to Alzheimer's amyloid β inhibits in vitro amyloid fibril formation. Neurobiol Aging 2004;25:1033-1043.
16. Shimode K, Kobayashi S, Imaoka K, Umegae N, Nagai A: Leukoencephalopathy- related cerebral amyloid angiopathy with cystatin C deposition. Stroke 1996;27:1417-1419.
17. Carrette O, Demalte I, Scherl A, et al: A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003;3:1486-1494.
18. Huang HM, Kuo YM, Ou HC, Lin CC, Chuo LJ: Apolipoprotein E polymorphism in various dementias in Taiwan Chinese population. J Neural Transm 2002;109:1415-1421.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
20. Morris JC: Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 1997;9(suppl 1):173-176.
21. Finney H, Newman DJ, Gruber W, Merle P, Price CP: Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem 1997;43:1016-1022.
22. Beyer K, Lao JI, Gomez M, et al: Alzheimer's disease and the cystatin C gene polymorphism: an association study. Neurosci Lett 2001;315:17-20.
23. Roks G, Cruts M, Slooter AJ, et al: The cystatin C polymorphism is not associated with early onset Alzheimer's disease. Neurology 2001;57:366-367.
24. Maruyama H, Izumi Y, Oda M, et al: Lack of an association between cystatin C gene polymorphisms in Japanese patients with Alzheimer's disease. Neurology 2001;57:337-339.
25. Monastero R, Camarda C, Cefalù AB, et al: No association between the cystatin C gene polymorphism and Alzheimer's disease: a case-control study in an Italian population. J Alzheimers Dis 2005;7:291-295.
26. Nacmias B, Bagnoli S, Tedde A, et al: Cystatin C and apoE polymorphisms in Italian Alzheimer's disease. Neurosci Lett 2006;392:110-113.
27. Galteau MM, Guyon M, Gueguen R, Siest G: Determination of serum cystatin C: biological variation and reference values. Clin Chem Lab Med 2001;39:850-857.
28. Sarnak MJ, Katz R, Stehman-Breen CO, et al: Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 2005;142:497-505.
29. Uzun H, Ozmen Keles M, Ataman R, et al: Serum cystatin C level as a potentially good marker for impaired kidney function. Clin Biochem 2005;38:792-798.
30. Mussap M, Plebani M: Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci 2004;41:467-550.
31. Coll E, Botey A, Alvarez L, et al: Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000;36:29-34.
32. Shi GP, Sukhova GK, Grubb A, et al: Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999;104:1191-1197.
33. Lindholt JS, Erlandsen EJ, Henneberg EW: Cystatin C deficiency is associated with the progression of small abdominal aortic aneurysms. Br J Surg 2001;88:1472-1475.
34. Noto D, Cefalu AB, Barbagallo CM, et al: Cystatin C levels are decreased in acute myocardial infarction: effect of cystatin C G73A gene polymorphism on plasma levels. Int J Cardiol 2005;101:213-217.
35. de la Torre JC: Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002;33:1152-1162.
36. Jellinger KA: Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 2002;109:813-836.
37. Launer LJ: Demonstrating the case that AD is a vascular disease: epidemiologic evidence. Ageing Res Rev 2002;1:61-77.
38. Benussi L, Ghidoni R, Steinhoff T, et al: Alzheimer disease-associated cystatin C variant undergoes impaired secretion. Neurobiol Dis 2003;13:15-21.
39. Haan J, Maat-Schieman ML, Roos RA: Clinical aspects of cerebral amyloid angiopathy. Dementia 1994;5:210-213.
40. Kumada T, Hasegawa A, Iwasaki Y, Baba H, Ikenaka K: Isolation of cystatin C via functional cloning of astrocyte differentiation factors. Dev Neurosci 2004;26:68-76.
41. Pawlik M, Sastre M, Calero M, et al: Overexpression of human cystatin C in transgenic mice does not affect levels of endogenous brain amyloid β peptide. J Mol Neurosci 2004;22:13-18.